Valeant Pharma (VRX) Relaunches Generic Ofloxacin Otic Solution for Bacterial Ear Infections

August 8, 2016 5:01 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced the relaunch of its generic ofloxacin otic solution to treat bacterial ear infections. The product was temporarily discontinued in April 2015 due to an issue concerning the active pharmaceutical ingredient supplier, which has been resolved.

Ofloxacin otic is a quinolone antibiotic solution used to treat outer ear infections in adults and children, chronic middle ear infections in adults and children with perforated eardrums, and acute middle ear infections in children with ear tubes. The product targets bacteria that cause the infection.

"We are pleased to relaunch this important product that improves the lives of a large population of children and adults who suffer from ear infections," said Joseph C. Papa, chairman and chief executive officer of Valeant. "Given the limited number of alternative products on the market, our team invested significant time and resources working with our active pharmaceutical ingredient supplier and the FDA to resolve this issue as quickly as possible. This relaunch demonstrates the strength of our generic portfolio, as well as our dedication to delivering effective and affordable treatments to patients."

The ofloxacin otic solution began shipping to customers on August 1, 2016 and will be available at most major retailers across the U.S.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Add Your Comment